Results 181 to 190 of about 169,996 (318)

Haemorrhage Associated with Combined Clopidogrel and Aspirin Therapy

, 2001
Todd Chapman, Douglas M. Bowley, A W Lambert, Andrew Walker, S. Ashley, David C. Wilkins   +5 more
openalex   +1 more source

Genetic determinants of response to clopidogrel and cardiovascular events.

New England Journal of Medicine, 2009
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. Steg, J. Ferrières, N. Danchin, L. Becquemont, Abstr Act   +10 more
semanticscholar   +1 more source

Appropriate Management of Thrombotic Risk in Patients With Primary Immune Thrombocytopenia in the UK: A Modified Delphi Consensus

eJHaem, Volume 6, Issue 5, October 2025.
ABSTRACT Introduction Immune thrombocytopenia (ITP) is characterised by a low platelet count and increased risk of bleeding. Recent research has also proposed that having ITP increases thrombosis risk. Moreover, certain ITP treatments have been associated with an increased risk of thrombosis.
Charlotte Bradbury, Jecko Thachil, Matthew McWilliams, Will A. Lester   +3 more
wiley   +1 more source

Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India. [PDF]

Sci Rep
Bharath G, Preethi L, Suriyam Nagappan A, Kalpana SR, Christopher R, Munirajan AK.   +5 more
europepmc   +1 more source

Acute Myocardial Infarction: Molecular Pathogenesis, Diagnosis, and Clinical Management

MedComm, Volume 6, Issue 10, October 2025.
Key pathogenic mechanisms in AMI. Oxidative stress and mitochondrial dysfunction induce ROS accumulation, while DAMPs‐PRRs interaction triggers inflammatory cascades. Programmed cell death pathways and epigenetic regulation collectively constitute the core components of AMI pathogenesis.
Mengmeng Zhu, Yiwen Li, Qian Xu, Wenting Wang, Yanfei Liu, Yue Liu   +5 more
wiley   +1 more source

Antiplatelet Therapy in Atrial Fibrillation Patients on Direct Oral Anticoagulants Undergoing Percutaneous Coronary Intervention: Which and How. [PDF]

J Clin Med
Martini L, Lisi M, Pompei G, Arioti M, Bendandi F, Henein MY, Cameli M, Rubboli A.   +7 more
europepmc   +1 more source

PCV2: COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION

, 2001
P Vorobiov, З. С. Баркаган, M Avxentieva, V Gerasimov, М. В. Сура, E.V. Derkach   +5 more
openalex   +1 more source

Clopidogrel before urgent coronary artery bypass graft [PDF]

, 2003
Michele Genoni, Reza Tavakoli, Christoph K. Hofer, Osmund Bertel, Marko Turina   +4 more
openalex   +1 more source

Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

New England Journal of Medicine, 2009
S. Connolly, J. Pogue, R. Hart, S. Hohnloser, M. Pfeffer, S. Chrolavicius, S. Yusuf   +6 more
semanticscholar   +1 more source

Demystifying Clone‐Censor‐Weighting to Studying Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 10, October 2025.
ABSTRACT Background Clone‐censor‐weighting (CCW) can compare treatment regimens that are initially indistinguishable (such as starting treatment within specific time windows) without using landmarks or creating immortal time. The causal contrasts estimated in these cases and the analyses themselves can become quite complex; however. Objective Provide a
Michael Webster‐Clark, Yi Li, Sophie Dell'Aniello, Robert W. Platt   +3 more
wiley   +1 more source